drugset / Trial / NCT00418535
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma
Phase 2
Completed
Samsung Medical Center
Asan Medical Center · collabGyeongsang National University Hospital · collabKorea University Anam Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Nasal NK/T-cell lymphoma is a peculiar clinico-pathologic subtype of non-Hodgkin's lymphoma (NHL). Although most patients present with stage I/II, only 30-60% of the patients remain disease-free. The efficacy of the conventional anthracycline-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone \[CHOPP\]) has been unsatisfactory. The optimal treatment of localized NK/T-cell lymphoma has not been defined yet. The optimal dose, sequence, and multi-modality treatment with involved field radiotherapy still need to be refined. This trial is to evaluate the efficacy of concurrent chemoradiotherapy with cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized NK/T-cell lymphoma patients.
Timeline
- Start
- 2006-04
- Primary completion
- 2009-03
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |